- Home
- DERM vs NYXH Comparison
DERM vs NYXH Comparison
Compare DERM & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DERM | NYXH |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 188.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DERM | NYXH |
|---|---|---|
| Price | $8.73 | $4.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $12.67 | $12.67 |
| AVG Volume (30 Days) | ★ 143.6K | 44.9K |
| Earning Date | 11-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,399,000.00 | $6,616,215.00 |
| Revenue This Year | $17.48 | $75.27 |
| Revenue Next Year | $55.83 | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.82 | ★ 10.96 |
| 52 Week Low | $3.63 | $4.35 |
| 52 Week High | $9.56 | $11.87 |
Technical Indicators
Market Signals| Indicator | DERM | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 46.63 |
| Support Level | $7.66 | $4.66 |
| Resistance Level | $9.00 | $5.00 |
| Average True Range (ATR) | 0.55 | 0.23 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 69.63 | 33.33 |
Price Performance
Historical ComparisonAbout DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.